Fostamatinib Nitroso Impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Fostamatinib is used to treat thrombocytopenia (less than normal number of platelets) in adults with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) who were not helped with another treatment.Fostamatinib Nitroso Impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Fostamatinib Nitroso Impurity 1 CAS NO:NA chemically represented as (6-((5-Fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)(nitroso)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate. Synchemia is the leading manufacturing and exporter of Fostamatinib Nitroso Impurity 1 . We supply Fostamatinib Nitroso Impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0141923 |
| CAS No | NA |
| Mol.F. | C19H23N3O5 |
| Mol.Wt. | 373.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141924 |
| CAS No | NA |
| Mol.F. | C18H21N3O5 |
| Mol.Wt. | 359.38 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141925 |
| CAS No | NA |
| Mol.F. | C20H25N3O5 |
| Mol.Wt. | 387.44 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141926 |
| CAS No | NA |
| Mol.F. | C17H20N2O2 |
| Mol.Wt. | 284.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141927 |
| CAS No | NA |
| Mol.F. | C17H20N2O2 |
| Mol.Wt. | 284.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141928 |
| CAS No | NA |
| Mol.F. | C19H23N3O5 |
| Mol.Wt. | 373.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141929 |
| CAS No | NA |
| Mol.F. | C18H23N3O4 |
| Mol.Wt. | 345.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141930 |
| CAS No | NA |
| Mol.F. | C18H21N3O5 |
| Mol.Wt. | 359.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141931 |
| CAS No | NA |
| Mol.F. | C20H25N3O5 |
| Mol.Wt. | 387.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141932 |
| CAS No | NA |
| Mol.F. | C32H35N7O7 |
| Mol.Wt. | 629.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141933 |
| CAS No | NA |
| Mol.F. | C34H39N7O7 |
| Mol.Wt. | 657.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141934 |
| CAS No | NA |
| Mol.F. | C32H36N8O6 |
| Mol.Wt. | 628.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141935 |
| CAS No | NA |
| Mol.F. | C33H38N8O6 |
| Mol.Wt. | 642.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141936 |
| CAS No | NA |
| Mol.F. | C8H6N3O5 |
| Mol.Wt. | 224.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141937 |
| CAS No | NA |
| Mol.F. | C9H7N3O3 |
| Mol.Wt. | 205.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0141938 |
| CAS No | NA |
| Mol.F. | C27H25N7O4 |
| Mol.Wt. | 511.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |